TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 210379
Drug: Neomycin-polymyxin irrigant
Normalized name: neomycin / polymyxin B Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin-polymyxin irrigant administered through closed urinary catheters
Study: 29171646
Drug: fast rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: fast rocuronium injection with saline
Study: 29171646
Drug: slow rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow rocuronium injection with remifentanil
Study: 29171646
Drug: fast rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: fast rocuronium injection with remifentanil
Study: 23836616
Drug: Systematic smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic smoking ascertainment and default provision of behavioural support and cessation pharmacotherapy during hospital stay; follow-up and referral to community services after discharge.
Study: 15193678
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg once daily
Study: 25849228
Drug: Oseltamivir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir treatment
Study: 11052557
Drug: Active supplements
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active supplements
Study: 31902864
Drug: Placebo supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplements
Study: 8257409
Drug: High-dose naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naltrexone
Study: 2859043
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg atenolol
Study: 31095810
Drug: Diluted single-phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted single-phase (DS; 1.6 ml/s)
Study: 31095810
Drug: Diluted biphasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted biphasic (DB; 9 ml @ 3.3 ml/s, 29 ml @ 1.4 ml/s)
Study: 25082346
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg QD
Study: 19583071
Drug: Gabapentin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (900 mg)
Study: 20175608
Drug: Structural Ecosystems
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structural Ecosystems Therapy (SET)
Study: 20490354
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment for 4 weeks
Study: 7387336
Drug: Beta-endorphin treatment
Normalized name: beta-endorphin human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-endorphin treatment
Study: 20974325
Drug: Test tablet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test tablet (20 mg)
Study: 10228298
Drug: Soy formula
Normalized name: Nursoy Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy formula (579 31 mL/d)
Study: 1778087
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg) - Spironolactone (100 mg) formulation 1
Study: 1778087
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg) - Spironolactone (100 mg) formulation 2
Study: 20093332
Drug: Conventional wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional wound treatment (Control)
Study: 3300383
Drug: Mezlocillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (2 doses)
Study: 8480929
Drug: Mezlocillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (3 doses)
Study: 30309244
Drug: TPH2 rs4570625
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPH2 rs4570625 (T-allele carriers: G/T or T/T genotypes)
Study: 16024973
Drug: G/G homozygotes
Approvals — FDA: no, EMA: no, PMDA: no
Description: G/G homozygotes
Study: 28489001
Drug: Noradrenergic blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenergic blockade (40 mg propranolol)
Study: 28489001
Drug: Dopamine D2/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2/3 receptor blockade (400 mg amisulpride)
Study: 22966986
Drug: ABT-102 (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-102 (2, 6, 18, 30 and 40 mg single dose; 2, 4 and 8 mg twice daily for 7 days; 1, 2 and 4 mg twice daily for 7 days)
Study: 8988926
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (15 mg)
Study: 3631029
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg trimoprostil
Study: 18208909
Drug: Reboxetine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (7 days treatment)
Study: 16826486
Drug: BRV-TV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV-TV vaccine
Study: 10426173
Drug: RRV-TV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV-TV vaccine
Study: 8165742
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg body weight over 3 days)
Study: 8165742
Drug: Sulfadoxine/pyrimethamine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine/pyrimethamine (standard doses)
Study: 22072492
Drug: Panobinostat (LBH589),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat (LBH589), oral administration
Study: 2312778
Drug: Metoprolol controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol controlled release tablets 100 mg CR/ZOK
Study: 2312778
Drug: Metoprolol conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol conventional tablets 100 mg (CT)
Study: 2312778
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg (ATL)
Study: 1221098
Drug: Antifibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrinolytic therapy
Study: 7000220
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antifibrinolytic therapy)
Study: 27546524
Drug: Topical estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estriol treatment (0.5 mg estriol ovules for 8 weeks)
Study: 27546524
Drug: Topical estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estriol treatment
Study: 23195924
Drug: Individualized methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized methadone dosages over 100 mg/day with voucher-based cocaine-targeted contingency management (CM)
Study: 23195924
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose increase from 70 mg/day to 100 mg/day
Study: 21950153
Drug: New pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New pharmaceutical equivalent tablet formulation containing 500 mg of SAQ mesylate
Study: 21950153
Drug: Innovator film
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovator film coated tablet formulation
Study: 8482988
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Statil (Ponalrestat)
Study: 3691679
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol (2.5 mg)
Study: 21621801
Drug: Low-fructose diet
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-fructose diet (<20 g/d)
Study: 11122832
Drug: Targeted alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted alpha particle therapy
Study: 3569230
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of glucose (trial G)
Study: 3569230
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of a sweetened placebo (trial C)
Study: 29445030
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg orally daily
Study: 30587441
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel 80 mg/m2 given 3 out of 4 weeks
Study: 27487463
Drug: Ofloxacin administered
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin administered one hour before IVI (every 15 minutes)
Study: 7633476
Drug: Combination Ho/Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Ho/Nd:YAG laser ablation
Study: 11252642
Drug: Lithium therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium therapy
Study: 31201188
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks treatment with oral doxycycline
Study: 31201188
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks treatment with oral doxycycline
Study: 20220046
Drug: Integrated glucose-insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated glucose-insulin model
Study: 11327626
Drug: 24h sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24h sodium excretion in premenopausal women
Study: 11327626
Drug: Cross-center correlation
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-center correlation analyses of 24h sodium excretion
Study: 8934963
Drug: Triazolam (0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.375 or 0.50 mg)
Study: 31161583
Drug: Internal medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal medicine residents and attending physicians
Study: 26853137
Drug: Continue antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue antihypertensive drugs
Study: 18165592
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone (1.5 mg) - Group M
Study: 17314337
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen of salmeterol (50 microg) plus fluticasone propionate (500 microg) twice daily
Study: 9457400
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous rIL-2 (720,000 IU/kg)
Study: 9457400
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous rIL-2 (72,000 IU/kg)
Study: 9457400
Drug: Subcutaneous outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous outpatient rIL-2 (week 1: 250,000 IU/kg/day for 5 of 7 days; weeks 2-6: 125,000 IU/kg/day for 5 of 7 days)
Study: 8032699
Drug: 5‐HT3 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT3 receptor antagonist (5‐HT3 RA)
Study: 3583492
Drug: Sulglycotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulglycotide (400 mg thrice daily)
Study: 20970833
Drug: Trospium XR
Normalized name: trospium Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospium XR 60 mg
Study: 11468201
Drug: Eptifibatide (180-microgram/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (180-microgram/kg bolus followed by 2 microgram/kg per minute infusion) with a second bolus of 90 microgram/kg
Study: 11468201
Drug: Eptifibatide (250-microgram/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (250-microgram/kg bolus followed by 3 microgram/kg per minute infusion) with a second bolus of 125 microgram/kg
Study: 10480221
Drug: 4 IU/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 IU/m2/day of recombinant human growth hormone (rhGH)
Study: 8067786
Drug: 2 IU/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 IU/m2/day of recombinant human growth hormone (rhGH)
Study: 8067786
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of rhGH
Study: 8067786
Drug: 3 years
Normalized name: NanoVM 1-3 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years of rhGH treatment
Study: 8067786
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year of rhGH treatment
Study: 3065157
Drug: Maalox TC
Normalized name: Aluminum Hydroxide/Magnesium Hydroxide 225 MG/5 ML-200 MG/5 ML Oral Suspension [MAALOX TC]
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox TC three tablets at bedtime (81 mmol)
Study: 3065157
Drug: Maalox TC
Normalized name: Aluminum Hydroxide/Magnesium Hydroxide 225 MG/5 ML-200 MG/5 ML Oral Suspension [MAALOX TC]
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox TC three tablets in the morning plus three tablets at bedtime (bd) (162 mmol)
Study: 2164771
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg at bedtime
Study: 30744672
Drug: Sensory Integration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory Integration Therapy (SIT)
Study: 19289619
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus trastuzumab (6 mg/kg body weight in 3-week cycles)
Study: 19289619
Drug: Capecitabine (2,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (2,500 mg/m2 on days 1 through 14)
Study: 11092994
Drug: Trandolapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2 mg/day, n = 8)
Study: 19210513
Drug: rizatriptan 5
Normalized name: rizatriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rizatriptan 5 mg
Study: 1347278
Drug: bismuth subsalicylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth subsalicylate, 600 mg three times daily (n = 19)
Study: 1347278
Drug: ranitidine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine, 300 mg at night (n = 20)
Study: 25538330
Drug: Silodosin 8
Normalized name: silodosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 8 mg once daily after dinner for 12 weeks
Study: 25538330
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg controlled release once daily for 12 weeks
Study: 11762414
Drug: Unlabeled antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unlabeled antibody therapy
Study: 2252531
Drug: Time of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time of beginning immunotherapy after onset of diabetes
Study: 908936
Drug: Bed rest
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bed rest (conservative treatment)
Study: 31755989
Drug: Postoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative oral corticosteroids (OCS) in descending doses plus nasal douching over a period of 4 weeks
Study: 3326525
Drug: Ketoconazole 800
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole 800 mg
Study: 11304893
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (HD, 7 mg/kg)
Study: 3672322
Drug: Intermittent sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sequential pneumatic compression alone
Study: 18761644
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (0.4 U/kg)
Study: 9220210
Drug: Doxazosin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (mean final daily dose of 2.8 mg)
Study: 8148213
Drug: Oily solution/suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily solution/suspension in miglyol
Study: 1421051
Drug: Teicoplanin 3
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 3 mg kg-1
Study: 1421051
Drug: Teicoplanin 30
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 30 mg kg-1
Study: 4082753
Drug: 16 microgram
Normalized name: Secretin 16 microgram powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 microgram dose of HBsAg vaccine
Study: 29433376
Drug: Pomegranate polyphenol
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate polyphenol supplementation (1 g of polyphenols, twice per day for one week)
Study: 29433376
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose pills, twice per day for one week)
Study: 29253180
Drug: Active music
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active music therapy intervention
Study: 29253180
Drug: Passive music
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive music therapy intervention
Study: 10201458
Drug: Dicyclomine (Dic)
DrugBank: Dicyclomine (DB00804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicyclomine (Dic) 20 mg four times daily
Study: 9395592
Drug: HIV antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV antibody testing, counseling and education programme
Study: 30717942
Drug: Psychosocial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychosocial intervention programme (six 90-min educational sessions, held weekly)
Study: 26911582
Drug: Intravenous exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous exenatide for up to 72 hours
Study: 31251546
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% cream
Study: 10069275
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of sufentanil (3.6 microg/kg/h) and midazolam (0.08 mg/kg/h)
Study: 10069275
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of sufentanil (2 microg/kg) and midazolam (0.03 mg/kg)
Study: 10069275
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of sufentanil and midazolam
Study: 10069275
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration
Study: 8179132
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion
Study: 10069275
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion and bolus administration
Study: 2033418
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus conventional chemotherapy (POG 8441)
Study: 11475180
Drug: Group F
Normalized name: Prostaglandin group F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group F + P + S (1.0 microgram/kg fentanyl and 0.5 mg/kg propofol prior to induction)
Study: 8052871
Drug: Etoposide 200
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 200 mg/m2 days 1 through 3 and vincristine 1.4 mg/m2 days 1 and 8 (EV)
Study: 478206
Drug: Domperidone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (two 10‐mg tablets t.i.d. before meals)
Study: 25530265
Drug: Micafungin 300
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micafungin 300 mg day(‐1) intravenous monotherapy
Study: 25530265
Drug: Control monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control monotherapy (lipid amphotericin B 5 mg kg(‐1) day(‐1), voriconazole 8 mg kg(‐1) day(‐1), or caspofungin 50 mg day(‐1))
Study: 3393382
Drug: Salbutamol (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.12 mg/kg) administered 300 minutes before exercise test
Study: 3393382
Drug: Clenbuterol (0.001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenbuterol (0.001 mg/kg) administered 300 minutes before exercise test
Study: 29096833
Drug: Atorvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin monotherapy (Control)
Study: 21668938
Drug: C6 injection
Normalized name: HYDROGENATED C6-20 POLYOLEFIN (100 CST)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C6 injection
Study: 21668938
Drug: C5 injection
Normalized name: dipentaerythrityl hexa C5-10 acid esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: C5 injection
Study: 9331308
Drug: Home intravenous
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home intravenous (IV) hydration after tonsillectomy
Study: 31983371
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS (2 mA, 20 min) combined with speech-language therapy
Study: 31983371
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS combined with speech-language therapy
Study: 27524671
Drug: Training group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training group with weekly bisphosphonate regimen
Study: 27524671
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with weekly bisphosphonate regimen
Study: 20816546
Drug: Oxygen delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen delivered via nasal cannula at 2 L per min for 7 days
Study: 20816546
Drug: Room air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room air delivered via nasal cannula at 2 L per min for 7 days
Study: 15922813
Drug: Stable dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable dosing of salmeterol/fluticasone propionate (SAL/FP) 50/250 microg BID